This article was originally published in The Tan Sheet
"The future promises increases in the number of drugs available OTC and in the variety of indications for their use," Eric Brass, MD/PhD, Harbor-UCLA Medical Center, writes in Sept. 13 NEJM. Former NDAC Chairman asserts technology advances may facilitate OTC therapy growth, noting "the wide availability and acceptance of reliable methods of measuring serum cholesterol in nonmedical settings may eventually contribute to the safety and effectiveness of OTC treatments for hyperlipidemia." Brass, whose term on NDAC ended in May, presided over the committee's consideration and rejection of switch applications for the statins Pravachol (BMS) and Mevacor (Merck) in July 2000
You may also be interested in...
Perrigo promotes in pricing, planning
Combe sells most of its OTC brands
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC